HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Actavis Laboratories

Division of Teva Pharmaceutical Industries Ltd.
www.andrx.com

Latest From Actavis Laboratories

US FDA Finds Negligible Cancer Risks In Metformin Products

The US FDA finds metformin meets NDMA impurity threshold and urges diabetics to continue taking it.

Manufacturing Quality

Diclofenac Reverse-Switched In Norway As Risks Outweigh Benefits

Norway becomes the latest country to reverse-switch diclofenac in response to a 2018 study linking low doses of the drug to cardiovascular adverse events. 

Drug Safety Regulation

Sweden Reverse-Switches Diclofenac Over Cardio Fears

Oral diclofenac will no longer be available without a prescription in Sweden after the national drug regulator judged that the potential adverse event risks were too high to justify continued OTC supply. Products from GSK and Mylan will be affected by the decision.

Regulation Prescription To Otc Switch

Foamix's Minocycline Foam: A Game Changer In Severe Acne?

A topical foam formulation of the antibiotic, minocycline, is expected to be a novel entrant into the US severe acne market. After positive top-line results from a confirmatory Phase III study, Foamix is stepping-up its financing and marketing plans.

Clinical Trials Dermatology
See All

Company Information

UsernamePublicRestriction

Register